Variational AI and Oncocross to Collaborate on AI-Driven Drug Discovery Program in Atopic Dermatitis
Variational AI announces a co-development agreement with Oncocross, to co-develop a novel small molecule inhibitor for chronic skin inflammation focusing on atopic dermatitis.
Accelerating the Discovery of Brain-Penetrant ATR Inhibitors with Enki™
Variational AI partnered with Rakovina Therapeutics to support the discovery of a brain-penetrant ATR inhibitor using our Enki™ generative AI platform. By generating and prioritizing novel, CNS-targeting compounds aligned with…
Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery
New funding to fuel market expansion of compute efficient foundation model for biopharmaceutical companies
How to drug a novel target in 500 molecules
Research conducted by the Variational AI team: Marshall Drew-Brook, Peter Guzzo, Ahmad Issa, Mehran Khodabandeh, Sara Omar, Jason Rolfe, and Ali Saberali. Searching through the space of synthesizable molecules to find an…
Variational AI Selected by ImmVue Therapeutics to Power Immuno-Oncology Drug Discovery
Immuno-Oncology pioneer ImmVue Therapeutics to adopt Enki™Lead Generator to discover first-in-class cancer drugs.
